VIR: Vir Biotechnology, Inc. Stock

by  •  • Comments Off on VIR: Vir Biotechnology, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 1,384.09
Enterprise Value ($M) 1,215.74
Book Value ($M) 1,240.73
Book Value / Share 9.01
Price / Book 1.12
NCAV ($M) 789.53
NCAV / Share 5.73
Price / NCAV 1.75

Profitability (mra)
Return on Invested Capital (ROIC) -0.39
Return on Assets (ROA) -0.28
Return on Equity (ROE) -0.34

Liquidity (mrq)
Quick Ratio 8.94
Current Ratio 8.94

Balance Sheet (mrq) ($M)
Current Assets 1,047.16
Assets 1,498.36
Liabilities 257.63
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
10-18 13G/A State Street Corp 4.10 -18.61
02-13 13G/A Vanguard Group Inc 9.14 21.82
02-13 13G/A Sb Investment Advisers (uk) Ltd 12.40
01-23 13G/A BlackRock, Inc. 12.50 19.30

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-04 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 o TRANSITION REPORT
2024-08-01 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 o TRANSITION REPORT PURS
2024-05-03 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 o TRANSITION REPORT PUR
2024-02-26 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-01-17 152,243 925,933 16.44
2025-01-16 228,428 1,123,804 20.33
2025-01-15 280,551 1,937,096 14.48
2025-01-14 327,525 1,656,205 19.78
2025-01-13 786,342 4,237,165 18.56

(click for more detail)

Similar Companies
UTHR – United Therapeutics Corporation VERV – Verve Therapeutics, Inc.
VIGL – Vigil Neuroscience, Inc. VOR – Vor Biopharma Inc.
VRTX – Vertex Pharmaceuticals Incorporated


Financial data and stock pages provided by
Fintel.io